Search company, investor...

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

About Noventure

Noventure manufacture and distributes medical devices. The company provides products for adults and children in indications ranging from gastroenterology, diarrhea, infant colic, IBSd, urology, treatment and prevention of uncomplicated UTI, vaginal candidiasis, dermatology, atopic dermatitis and ENT, rhinitis treatment and prevention, and further applications of the technology in preparation. It is based in Barcelona, Spain.

Noventure Headquarters Location

Av. Diagonal 549 5a planta

Barcelona, 08029,


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Noventure News

Noventure Acquires Two Medical Devices for Wound Healing

Jun 11, 2021

Noventure Acquires Two Medical Devices for Wound Healing The products contain Olea Europaea leaf extract, showing healing properties for ulcers and skin wounds. Image courtesy of Noventure. Noventure06.11.21 Noventure , specialized in licensing innovative substance-based medical devices and specialist food supplements, has acquired the Ulkox and Oleoabrax products, based on an Olea Europaea leaf extract wound-healing technology. These medical devices were originally developed by Spanish companies Quesper R&D, specializing in the creation and development of medical devices with a markedly innovative character, and Orpea Ibérica, a leading company in Spain in the fields of care for the elderly and dependent people, and the mental health sector, together with the Andalusian Health Service (Servicio Andaluz de Salud, SAS). Olea Europaea (olive) leaf extract  has shown excellent scavenging effects  that contribute to the acceleration of the healing of skin wounds. Chronic wounds are mostly seen in the elderly population. Increasing costs of health care, an aging population, recognition of difficult-to-treat infection threats such as biofilms, and the continued threat of diabetes and obesity worldwide, make chronic wounds a substantial clinical, social and economic challenge. From an economic point of view, the  annual wound care products market  is expected to reach $15–22 billion by 2024. “This agreement will enable us to keep shaping innovative science assets and bring them to markets around the world, and to take steps towards becoming a key player in medical devices for topical applications. This is only the beginning; we have many innovative products that we will be able to bring to patients, thanks to this patented new technology,” said Luciano Conde, CEO of Noventure. Ulkox and Oleoabrax are the first Olea Europaea-based products for Noventure. They are already available for licensing and have been certified as Class IIb medical devices. They are indicated for healing skin wounds of full or partial thickness. As amorphous hydrogels, they protect the affected area from infection and boost healing based on four properties: the protective barrier, skin hydration, pH control and oxygen radical scavenging effect. These patent-protected products are easy to apply and are  supported by proven evidence  from robust experimental and clinical research. "Following more than 10 years of preclinical and clinical research, we can proudly state that Ulkox and Oleoabrax have the proven ability to reactivate and accelerate the healing process of ulcers and skin wounds, and do so significantly better than other widely-used products," said Jose Manuel Quesada, CEO of Quesper R&D. "Their introduction into the market will mean a significant improvement in patients’ quality of life, as well as being an important advance for the professionals who care for them. We therefore welcome the transfer of this disruptive technology to Noventure, which will make our products available to patients all over the world." Ulkox and Oleoabrax are class IIb medical devices which comply with the essential requirements of Directive 93/42/EEC and subsequent amendments. (CE 0318, Ferrer Internacional, S.A.) They will initially be marketed in the European Union. Regulatory steps are being taken to make them readily available throughout the rest of the world. An Orpea representative spoke of its medical and healthcare teams: “working daily to develop innovative programs, therapies and treatments that provide greater well-being and quality of life for the elderly. Research and innovation are the two pillars that allow us to be worldwide leaders in the sector of dependency and care for the elderly.”   Quesper R&D is a technology-based company specialising in the creation and development of medical devices with a markedly innovative character. The company covers all stages of product development—up to obtaining the CE-mark—basing its strategy on the generation of scientific evidence of the highest quality, this allows it to differentiate its medical devices from those already on the market. Related Breaking News Business Wire 06.11.21 Business Wire 06.11.21 GlobalData 06.11.21 Zeus Industrial Products Inc. 06.10.21 PR Newswire 06.10.21 Getinge 06.10.21 Business Wire 06.10.21 Xandar Kardian 06.10.21 Business Wire 06.10.21 PR Newswire 06.10.21 GlobalData 06.10.21 Business Wire 06.10.21 Business Wire 06.09.21 Business Wire 06.09.21 Business Wire 06.09.21

  • Where is Noventure's headquarters?

    Noventure's headquarters is located at Av. Diagonal 549, Barcelona.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.